Tki + blinatumomab for neoplasm, residual

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 May 2015: Trial registered, NCT02458014
  2. 14 Sep 2015: Trial started, NCT02458014

The trials

NCT02458014: Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

State
Completed
Phase
Phase 2
People
37 taking part
Started
14 Sep 2015
Primary completion
16 Sep 2025
Arms
Treatment (blinatumomab + TKI)
Results
Posted on the registry
  1. 29 May 2015: Trial registered
  2. 14 Sep 2015: Trial started
  3. 16 Sep 2025: Trial completed
  4. 25 Sep 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.